Zenas BioPharma, Inc. (ZBIO)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Zenas BioPharma, Inc. reported revenue of $10.00M, up 100.0% from the prior year. The company ran a net loss, with a net margin of -3777.4%. It held $383.64M in total assets against $141.50M in total liabilities.
Key ratios (FY2025)
-3830.6%
Operating margin
-3777.4%
Net margin
-156.0%
Return on equity
+100.0%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $10.00M | $5.00M | $50.00M | — |
| Operating Income | -$383.06M | -$163.89M | -$37.15M | — |
| Net Income | -$377.74M | -$156.99M | -$37.12M | — |
| EPS (Diluted) | $-8.44 | $-11.89 | $-24.25 | — |
| Total Assets | $383.64M | $369.97M | $68.18M | — |
| Total Liabilities | $141.50M | $57.51M | $43.81M | — |
| Shareholders' Equity | $242.14M | $312.46M | -$225.72M | -$192.29M |
| Cash & Equivalents | $110.64M | $319.74M | $56.86M | — |
| Operating Cash Flow | -$172.33M | -$119.67M | -$30.53M | — |
| Capital Expenditures | $18.0K | $131.0K | $17.0K | — |
| Shares Outstanding | 54.49M | 41.79M | 1.58M | — |